<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917524</url>
  </required_header>
  <id_info>
    <org_study_id>CTCNGS002</org_study_id>
    <secondary_id>MOST104-2314-B-182A-073-MY3</secondary_id>
    <nct_id>NCT03917524</nct_id>
  </id_info>
  <brief_title>Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.</brief_title>
  <acronym>CTC</acronym>
  <official_title>The Feasibility of Circulating Tumor Cells Isolation for Transcriptomes and Genome-wide Associated Analysis in Post-surgically High-risk Oral Cavity Cancer Patients and Its Clinical Significance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-cancer treatments have been thought to be closely related to their unique genetic&#xD;
      alterations. In the past few years, the investigator have used cDNA microarray to delineate&#xD;
      the transcriptome profiles of differentially-expressed genes between OSCC tumors and normal&#xD;
      epithelium. By supervised hierarachical clustering analysis, the investigator further&#xD;
      analyzed and validated the differentially-expressed genes for OSCC tumors. In the&#xD;
      investigators' previous research, the investigators have used this strategy to analyze the&#xD;
      potential tissue proteins associated with OSCC tumors, indicating the feasibility of this&#xD;
      strategy. However, gene detection is a great limitation and challenge in CTCs researches&#xD;
      owing to the small number of isolated cells by traditional methods. Fortunately, by means of&#xD;
      the investigators' developing high-purity CTCs isolation techniques, some preliminary data&#xD;
      implied that isolated CTCs by this method could achieve the criteria of Whole-genome analysis&#xD;
      (WGA), which brings the investigators' passion for further investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First Year&#xD;
&#xD;
      1. Negative Selection Method 2. Positive Selection method (Dynabeads) 3. ODEP devices 4. Flow&#xD;
      Cytometry and Sorting System 5. Cell lines for Positive control Second Year &amp;Third year&#xD;
&#xD;
        1. Clinical Trial, Patient Enrollment and Design of Schedule&#xD;
&#xD;
           The Inclusion criteria and aims are as followings:&#xD;
&#xD;
             1. Patients with oral cavity squamous cell carcinoma (n=180), with age at diagnosis ≥&#xD;
                20 years, will be enrolled before surgery at Ear-Nose-Throat department inpatient&#xD;
                or outpatient service by Dr. Liao, Dr. Hsieh, Dr. Wang and co-PIs.&#xD;
&#xD;
             2. All patients will be subgrouped by pathologic features and risk factors Group A&#xD;
                (n=90): OSCC, post-surgery, no need for any adjuvant therapy Group B (n=90): OSCC,&#xD;
                post-surgery, with major risk factor(s) or 2 minor risk factors Stratification by&#xD;
                Risk factors, alcohol, betel nut chewing and cigarette use status&#xD;
&#xD;
             3. Testing: Circulating tumor cells (CTCs) (x4) and NGS for WGA and transcriptomes&#xD;
                (x4)&#xD;
&#xD;
             4. Endpoints: Loco-regional recurrence, one-year distant metastasis rate, death,&#xD;
                second primary tumor occurrence.&#xD;
&#xD;
             5. Exclusion criteria are: (1) Patient's refusal; (2) Poor compliance, cannot&#xD;
                cooperate for blood sampling for CTCs isolation as time schedule or clinical&#xD;
                treatment or follow-up (3) Difficult blood sampling; (4) No more needs for CTCs&#xD;
                evaluation, decided by clinicians.&#xD;
&#xD;
        2. Whole-Genome Analysis for Cancer Tissue Samples/Circulating Tumor Cells When needed,&#xD;
           OncoScan™ FFPE Express Extraction will be performed&#xD;
&#xD;
           Requirements need to be observed when submitting FFPE slices:&#xD;
&#xD;
           Slices should be sent in 1.5mL conical vials Tumor samples in sections should have a&#xD;
           surface area of 100 square mm (Minimum) to 1000 square mm (Maximum).&#xD;
&#xD;
           Normal samples in sections should have a surface area of 200 square mm (Minimum) to 1000&#xD;
           square mm (Maximum).&#xD;
&#xD;
           Section thickness should be 10 micron. The range of sections acceptable per sample is&#xD;
           2-6. Slices for OncoScan analysis and immunohistochemistry study are separated; and will&#xD;
           be doubly charged by the Dep. of Clinical Pathology.&#xD;
&#xD;
           The QIAamp DNA FFPE Tissue Kit is optimized for purification of DNA from FFPE tissue&#xD;
           sections.&#xD;
&#xD;
           OncoScan™ Express Samples will be performed in Chang Gung Memorial Hospital 1J GMRCL&#xD;
           CoreLab or Chang Gung University Labs for whole-genome analysis.&#xD;
&#xD;
        3. Negative Selection Method&#xD;
&#xD;
        4. Positive Selection method (Dynabeads)&#xD;
&#xD;
        5. ODEP devices&#xD;
&#xD;
        6. Flow Cytometry and Sorting System&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>one year</time_frame>
    <description>Measure response or progression events via all available imaging studies, including Chest-Xray, CT scans, or MRI, Positron Emission Tomography(PET)study. The relationship between CTCs number and time from CTCs checkpoint to disease progression will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>one year</time_frame>
    <description>All causes of death would be documented and the relationship between CTCs number and time from CTCs checkpoint to death will be analyzed.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Oral Cavity Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>no need for any adjuvant therapy</arm_group_label>
    <description>Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>with risk factors</arm_group_label>
    <description>Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with oral cavity squamous cell carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with oral cavity squamous cell carcinoma (n=180), with age at diagnosis ≥ 20&#xD;
             years, will be enrolled before surgery at Ear-Nose-Throat department inpatient or&#xD;
             outpatient service by Dr. Liao, Dr. Hsieh, Dr. Wang and co-PIs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Patient's refusal; (2) Poor compliance, cannot cooperate for blood sampling for&#xD;
             CTCs isolation as time schedule or clinical treatment or follow-up (3) Difficult blood&#xD;
             sampling; (4) No more needs for CTCs evaluation, decided by clinicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chun-Ta Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Otolaryngology, Chang Gung Memorial Hospital at Linkou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yo-Ting Hsueh</last_name>
      <phone>03-3196200</phone>
      <phone_ext>3703</phone_ext>
      <email>sally6869@cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chia-Hsun Hsieh, M.D,M.S.</last_name>
      <phone>+886-33281200</phone>
      <phone_ext>8825</phone_ext>
      <email>wisdom5000@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chia-Hsun Hsieh, M.D, M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Ta Liao, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Ming Wang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Yu Lin, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tzu-Chen Yen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Yu Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Cavity Cancer</keyword>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>Whole-genome analysis</keyword>
  <keyword>transcriptomes</keyword>
  <keyword>distant metastasis</keyword>
  <keyword>locoregional recurrence</keyword>
  <keyword>second primary tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

